Ultrasound thrombolysis

2005 ◽  
Vol 94 (07) ◽  
pp. 26-36 ◽  
Author(s):  
Stefan Pfaffenberger ◽  
Branka Devcic-Kuhar ◽  
Stefan P. Kastl ◽  
Gerald Maurer ◽  
Johann Wojta ◽  
...  

SummaryCardiovascular diseases are a major cause of mortality in the developed world. Efficacy of thrombolysis plays an important role in the management of acute myocardial infarction and cerebral insult both in the acute event and in the long-term outcome of these patients. New adjunctive strategies have been tested, therefore, to make thrombolytic therapies more effective and safer. Ultrasound Thrombolysis is a technique which showed promising results under in vitro conditions and in animal studies. Now clinical trials have to prove if it is also feasible for clinical application. This report gives an overview on different technical approaches and their current performances in the clinical setting. All original articles are chronologically ordered in tables providing detailed information on each study concerning experimental design, acoustical parameters and thrombolysis outcome.

2018 ◽  
Vol 71 (11) ◽  
pp. A246
Author(s):  
Nitinan Chimparlee ◽  
Jarkarpun Chaipromprasit ◽  
Siriporn Athisakul ◽  
Vorarit Lertsuwunseri ◽  
Wacin Buddhari ◽  
...  

2003 ◽  
Vol 89 (2-3) ◽  
pp. 207-215 ◽  
Author(s):  
Jacob E. Møller ◽  
Steen H. Poulsen ◽  
Eva Søndergaard ◽  
James B. Seward ◽  
Christopher P. Appleton ◽  
...  

2019 ◽  
Author(s):  
Rui Xiang ◽  
Min Mao ◽  
Ping Tang ◽  
Jun Gu ◽  
Kanghua Ma

Abstract Background: Cysteine-rich angiogenic inducer 61 (Cyr61) is a matricellular protein participating in the angiogenesis, inflammation, and fibrotic tissue repair. Previous study has proven its value in diagnosing and risk stratification of ST-elevation myocardial infarction (STEMI). However, there is no study focusing on Cyr61 and the long-term outcome of STEMI. Methods: A total of 426 patients diagnosed with STEMI were enrolled in this study. Blood sample was acquired 24 hours after the admission. The patients were required long-term follow-up after the discharge, when primary endpoint of all-cause death and secondary endpoint of cardiac complications were observed. Cox hazard ratio model and survival analysis were used to compare the risk of patients with higher level and lower level of Cyr61. Results: We conducted an average of (48.4 ± 17.8) months of follow-up, during which a total of 28 deaths happened (6.6%), while 106 episodes of secondary endpoints occurred (24.9%). Patients with higher quartile (Q4) Cyr61 were at higher risk of death [HR 3.404 95%CI (1.574-7.360), P<0.001] when compared with lower three quartiles (Q1-Q3) Cyr61. In terms of secondary endpoints, patients with Q4 Cyr61 were subject to 4.718 [95%CI (3.189-6.978) , P<0.001] times of risk compared with Q1-Q3 Cyr61. Conclusions: For STEMI Patients, those with increased Cyr61 have higher risk of all-cause death and cardiac complications. Therefore, Cyr61 may be a useful tool in predicting the long-term prognosis of STEMI.


2020 ◽  
Vol 46 (6) ◽  
pp. 1435-1441
Author(s):  
Bo Hu ◽  
Qing Zhou ◽  
Xue Yao ◽  
Tuantuan Tan ◽  
Jiarui Lei ◽  
...  

Cardiology ◽  
1997 ◽  
Vol 88 (5) ◽  
pp. 460-467 ◽  
Author(s):  
Lynette L.-Y Lim ◽  
Scott Kinlay ◽  
Janet D Fisher ◽  
Annette J Dobson ◽  
Richard F Heller

Sign in / Sign up

Export Citation Format

Share Document